Drug Approval | August 27, 2022
Lupin receives UK MHRA Approval of Lutio for treatment of COPD
Lutio has the potential to offer significant cost savings when available to UK patients.
Lutio has the potential to offer significant cost savings when available to UK patients.
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The clinical research organisation located in Hyderabad is a USFDA inspected facility
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Subscribe To Our Newsletter & Stay Updated
